CytomX Therapeutics, Inc. (CTMX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
CTMX Revenue Analysis (2013–2024)
As of February 28, 2026, CytomX Therapeutics, Inc. (CTMX) generated trailing twelve-month (TTM) revenue of $113.6 million, reflecting significant decline in growth of -82.2% year-over-year. The most recent quarter (Q3 2025) recorded $6.0 million in revenue, down 68.0% sequentially.
Looking at the longer-term picture, CTMX's 5-year compound annual growth rate (CAGR) stands at +19.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $138.1 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), CTMX has underperformed the peer group in terms of revenue growth. Compare CTMX vs REGN →
Peer Comparison
Compare CTMX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CTMXCurrent | $114M | -82.2% | +19.2% | 18.1% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $138.1M | +36.4% | $138.1M | 100.0% | $25.0M | 18.1% |
| 2023 | $101.2M | +90.4% | $101.2M | 100.0% | $-6,484,000 | -6.4% |
| 2022 | $53.2M | +42.5% | $53.2M | 100.0% | $-101,335,000 | -190.6% |
| 2021 | $37.3M | -45.5% | $37.3M | 100.0% | $-116,042,000 | -311.0% |
| 2020 | $68.4M | +19.0% | $68.4M | 100.0% | $-80,540,000 | -117.7% |
| 2019 | $57.5M | -3.4% | $57.5M | 100.0% | $-110,895,000 | -192.9% |
| 2018 | $59.5M | -16.9% | $59.5M | 100.0% | $-77,874,000 | -130.9% |
| 2017 | $71.6M | +376.1% | $71.6M | 100.0% | $-46,259,000 | -64.6% |
| 2016 | $15.0M | +95.1% | $15.0M | 100.0% | $-59,586,000 | -396.1% |
| 2015 | $7.7M | +51.9% | $7.7M | 100.0% | $-33,203,000 | -430.5% |
See CTMX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTMX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CTMX vs AGIO
See how CTMX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CTMX's revenue growth accelerating or slowing?
CTMX revenue declined -82.2% year-over-year, contrasting with the 5-year CAGR of +19.2%. TTM revenue fell to $114M. This reverses the prior growth trend.
What is CTMX's long-term revenue growth rate?
CytomX Therapeutics, Inc.'s 5-year revenue CAGR of +19.2% reflects the variable expansion pattern. Current YoY growth of -82.2% is below this long-term average.
How is CTMX's revenue distributed by segment?
CTMX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.